I am a results-driven professional passionate about making life-changing medicines for patients. With 20 years of experience in autoimmune, cancer, and neurodegeneration therapeutic areas, I have broad expertise in pre-clinical and translational development of multiple small molecule modalities, including reversible and covalent inhibitors, protein degradation, protein stabilizers, and protein-protein inhibitors. I have established mechanistic screening approaches that have led to the discovery of unique chemical spaces.
As a leader, manager, and team player, I have a successful track record of driving and meeting milestones from target discovery to IND submission. I have contributed to 10 IND documents, with one being successful in a phase 1B RA clinical trial. I have managed matrix teams globally, both internally and in collaboration with KOLs and academic scientists, and have experience in retaining and recruiting scientific talent.
My experience highlights include defining strategies for screening approaches, successfully managing a diverse portfolio of preclinical targets from target identification to candidate selection in cancer and autoimmune diseases, and leading matrix project teams to deliver IND candidates and enable critical go/no-go decisions. I have provided updates on the portfolio to senior management, including in- or out-licensing opportunities and managing external collaborations.
Key Milestone Expertise in Drug Discovery & Development:
- Hit Identification
- Lead Identification
